A phase II, randomized, open-label study to evaluate low-dose pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy for localized triple-negative breast cancer (TNBC) (PLANeT trial-Pembrolizumab Low dose in Addition to NACT in TNBC)
OncologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Annals of oncology : official journal of the European Society for Medical Oncology
- Publicado em
- 22 dez 2025
- Citações
- 12
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
A phase II, randomized, open-label study to evaluate low-dose pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy for localized triple-negative breast cancer (TNBC) (PLANeT trial-Pembrolizumab Low dose in Addition to NACT in TNBC)
A Arora, H Bhaskarane, G Tansir, S Bakhshi, A Gogia, A Kumar, R Jain, K Kalra, D Vishvam, S Mathur et al.
Descritores MeSH
- Antineoplastic Combined Chemotherapy Protocols
- Neoadjuvant Therapy
- Antibodies, Monoclonal, Humanized
- Triple Negative Breast Neoplasms
- Female
- Adult
- Middle Aged
- Paclitaxel
- Humans
- Aged